Welcome to our dedicated page for Nls Pharmaceutics SEC filings (Ticker: NLSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NLS Pharmaceutics Ltd. filings document the company's transition into NewcelX Ltd. following the completed merger with Kadimastem and the regulatory reporting of a clinical-stage biotechnology issuer. Recent Form 6-K reports furnish press releases, investor materials, governance updates, and current-event disclosures for programs in neurodegenerative and metabolic diseases.
The filing record includes foreign private issuer disclosures tied to material agreements, shareholder voting matters, capital-structure items, security-structure disclosures, executive and advisory governance changes, clinical or regulatory communications, and operating and financial results. These filings also reference pipeline subjects such as AstroRx, the AEX-6xx CNS series, and ITOL-102.
NewcelX Ltd., a Switzerland-based biotechnology company, reported that it issued a press release announcing the appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute, to its Scientific Advisory Board. The filing highlights that this appointment is intended to strengthen NewcelX’s scientific advisory capabilities by adding an experienced clinical leader to its advisory structure.
NewcelX Ltd. (NLSP) appointed Omri Hagai as Chief Financial Officer, effective December 10, 2025. He succeeds Interim CFO Uri Ben Or, who will step down the same day. The company stated Mr. Ben Or’s departure was not due to any disagreement with NewcelX regarding operations, policies, or practices.
The appointment follows the closing of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. Mr. Hagai brings public‑company finance experience from Israel Chemicals, BrainsWay, and Saverone, and is a CPA in Israel.
NewcelX Ltd. filed Post‑Effective Amendment No. 2 to its Form F‑4, stating that it is being filed solely to (i) include Rule 473(b) language for automatic effectiveness 20 days following this filing, (ii) update the registrant’s name, and (iii) file updated Exhibits 23.2, 23.4 and 24.1; it does not modify the prospectus.
NLS Pharmaceutics previously registered 70,000,000 common shares and up to 70,000,000 pre‑funded warrants to purchase 70,000,000 NLS common shares in connection with the transaction. Shareholders approved the merger on September 29, 2025, setting the final ownership split at approximately 84.4% for Kadimastem holders and 15.6% for NLS holders. The merger closed on October 30, 2025, and NewcelX common shares began trading on Nasdaq as “NCEL” on October 31, 2025; the last reported sale price on November 4, 2025 was $5.65.
As of June 30, 2025, NLS reported cash and cash equivalents of $3.1 million and an accumulated deficit of $74.8 million, with a net loss of $2.22 million for the six months ended June 30, 2025. Kadimastem reported a net loss of $11.2 million for the same period, largely due to non‑cash revaluation of convertible loans, and cash of $298,932. Both parties highlight going‑concern risks and the need for additional financing.
NewCelX Ltd. filed a Form 6-K to furnish a press release and investor presentation issued on November 3, 2025. The materials provide a business and strategic roadmap update following the closing of NewCelX’s merger with NLS Pharmaceutics Ltd.
The filing itself mainly serves to formally provide these two documents to investors and regulators as Exhibits 99.1 and 99.2.
NLS Pharmaceutics (NLSP) completed its merger with Kadimastem on October 30, 2025, combining operations to form an integrated biopharmaceutical company focused on cell-based and small‑molecule therapies for neurodegenerative and metabolic diseases. In connection with closing, the company implemented a 1‑for‑10 reverse stock split and changed its name to NewcelX Ltd.
Shareholders approved the transactions on September 29, 2025. As part of closing, holders of NLS common shares, preferred shares, preferred participation certificates, and warrants received contingent value rights tied to potential future net proceeds from certain legacy asset dispositions, including Mazindol ER and excluding the DOXA platform.
NLS Pharmaceutics Ltd. filed a report noting that it issued a new press release about expanding its central nervous system (CNS) drug pipeline. The press release, titled “NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs,” highlights a new series of CNS-focused compounds originating from Aexon Labs.
This step signals that NLS Pharmaceutics is adding additional product candidates to its research portfolio, potentially broadening its future development opportunities in neurological or psychiatric conditions, although no clinical, financial, or deal terms are described in this report.
NLS Pharmaceutics Ltd. furnished a 6-K reporting that, on October 29, 2025, it issued a press release titled “NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger.” The press release is included as Exhibit 99.1.
The filing indicates the company is highlighting ongoing support for the ITOL-102 diabetes program in the context of its merger with Kadimastem. The report is administrative in nature and provides the press release as an exhibit for investors’ reference.